Discussion in 'Food and nutrition' started by expo, Jan 16, 2006.

  1. expo

    expo Guest


    Weston, Florida, January 14, 2006

    Cytorex Biosciences, Inc. (Cytorex), a Florida based biotechnology
    company, announced today the publication in the January 2006 issue of
    the Journal of Carcinogenesis, of a research report related to in-vitro
    efficacy testing in cancer cell lines and normal cell lines, with
    Cytoreg®, their lead anti-cancer compound.

    The title of the publication is: "Cytoreg® inhibits growth and
    proliferation of human adenocarcinoma cells via induction of
    apoptosis". The corresponding author is James Kumi-Diaka, DVM, PhD,
    from Florida Atlantic University (FAU), and the co-authors of the
    report are: Manzur Hassanhi, MD, PhD , professor of Immunology and
    Cancer Research Scientist, from the University of Zulia (Venezuela),
    Brown Jayaan(FAU), Kendra Merchant (FAU) , Carlos M Garcia (Cytorex),
    and William Jimenez (Cytorex).

    Abstract: "Cancer is one of the devastating neovascular diseases that
    incapacitate so many people the world over. Recent reports from the
    National Cancer Institute indicate some significant gain therapy and
    cancer management as seen in the increase in the 5-year survival rate
    over the past two decades. Although near-perfect cure rate have been
    reported in the early-stage disease, these data reveal high recurrence
    rate and serious side effects including second malignancies and
    fatalities. Most of the currently used anticancer agents are only
    effective against proliferating cancer cells. Thus attention has been
    focused on potential anti-cancer agents capable of killing cancer cells
    independent of the cell cycle state, to ensure effective elimination of
    most cancer cells. The objective of this study was to test the
    Chemosensitivity and potential mechanism of action of a novel cancer
    drug, Cytoreg®, in a panel of human cancer cells. Methods: the study
    was performed using a series of bioassays including Trypan blue
    exclusion, MTS Growth inhibition, LDH-cytotoxicity, TUNEL-Terminal DNA
    fragmentation Apoptosis Assay, and the Caspase protease CPP32 activity
    assays. Results: Cytoreg® induced significant dose- and time-dependent
    inhibition of growth in all the cells; with significant differences in
    chemosensitivity (P 1:300). Cytoreg®-induced caspase protease-3
    (CPP32) activation significantly and positively correlated with
    apoptosis induction and growth inhibition; thus implicating CPP32 as
    the principal death pathway in Cytoreg®-induced apoptosis. Conclusion:
    Cytoreg® exerted a dose-and time-dependent growth inhibitory effect in
    all the target cells through induction of apoptosis via the CPP32 death
    pathway, independent of hormonal sensitivity of the cells. The present
    data indicate that not only could CPP32 provide a potential target for
    regulation of Cytoreg®-induced apoptosis but also that Cytoreg® could
    play a significant role in chemotherapeutic regimen in many human
    malignant tumors."

    "This is the first of several research reports about Cytoreg® we
    plan to submit, during 2006. to peer-reviewed journals", said Dr.
    James Kumi-Diaka, Professor of Biology of Cancer at Florida Atlantic
    University in Davie, Florida.

    "Cytoreg® has great potential as an anti-cancer compound, and
    additional research has shown that this compound's toxicity level is
    very low if compared with current approved chemotherapeutical
    agents", indicated Dr. Manzur Hassanhi, Professor of Immunology and
    Cancer Research Scientist of the University of Zulia

    Both Kumi-Diaka and Hasannhi, have lead since 2003 a multinational
    research team involved in the discovery of Cytoreg® as an anti-cancer

    According to Cytorex's Vice-President & CFO, William Jimenez, who is
    also a co-author of this research report, "Cytoreg® is a therapeutic
    agent for cellular regulation, with antineoplastic properties which may
    also be used to fight immunological diseases. Cytoreg® constitutes a
    balanced mixture of strong and weak acids in an aqueous medium;
    resembling a buffer without using salts. Cytoreg® is transferred into
    a cellular system through ionic transport due to its low molecular
    weight, where each ion acts concurrently in cells, turning Cytoreg®
    into a highly efficient "smart-drug." Cytoreg®'s numerous
    mechanisms of action are exerted through the cellular membrane".

    A complete PDF version of the report is can be accessed through the
    Journal of Carcinogenesis web page:


    For more information, please contact: 1-954-937-8519 USA), or send an
    email message to: [email protected] .